
IDEAYA Biosciences, a California-based biotech firm, develops oncology-focused drugs for cancer treatment.
IDEAYA Biosciences, founded in South San Francisco, California, is a clinical-stage precision medicine oncology company. The company's core mission is to improve lives through transformative precision medicines. IDEAYA focuses on developing targeted therapeutics for cancer treatment, specifically for patient populations selected using molecular diagnostics. Their primary area of expertise is synthetic lethality, an emerging class of precision medicine targets.
Notable affiliated people include prominent scientists and industry leaders who have significantly contributed to the field of oncology. IDEAYA has garnered substantial investment from leading venture capital firms and strategic partners in the healthcare sector. Key achievements include advancing several first-in-class and best-in-class therapeutics into clinical trials, demonstrating significant potential in cancer treatment. The company's impact is marked by its innovative approach to precision medicine, aiming to provide more effective and personalized cancer therapies.

Synnovation Therapeutics
synnovationtx.com

Immune-Onc Therapeutics
immuneonc.com

Sutro Biopharma
sutrobio.com

Akoya Biosciences
akoyabio.com

Iyuda Therapeutics

Revolution Medicines
revmed.com

Iovance Biotherapeutics
iovance.com

Tango Therapeutics
tangotx.com

Massive Bio
massivebio.com

Whitehawk Therapeutics
aadibio.com

Twist Bioscience

HI-Bio
hibio.com

Precision BioSciences

BridgeBio Pharma
bridgebio.com

SunnyBay BioTech
Companies similar to Ideaya Biosciences include Synnovation Therapeutics, Immune-Onc Therapeutics, Sutro Biopharma and Akoya Biosciences.
Ideaya Biosciences was founded in 2015.
Ideaya Biosciences' headquarters is located in South San Francisco, CA, US.
Ideaya Biosciences' most recent funding round was for $125M (USD) in October 2023.
As of Oct 24, 2023, Ideaya Biosciences has raised a total of $431.1M (USD).
Ideaya Biosciences has 103 employees as of Feb 6, 2024.